EP1178832A1 - Nouvelles compositions medicamenteuses a base de composes a action anticholinergique et de betamimetiques - Google Patents

Nouvelles compositions medicamenteuses a base de composes a action anticholinergique et de betamimetiques

Info

Publication number
EP1178832A1
EP1178832A1 EP00929478A EP00929478A EP1178832A1 EP 1178832 A1 EP1178832 A1 EP 1178832A1 EP 00929478 A EP00929478 A EP 00929478A EP 00929478 A EP00929478 A EP 00929478A EP 1178832 A1 EP1178832 A1 EP 1178832A1
Authority
EP
European Patent Office
Prior art keywords
methyl
long
hydroxy
optionally
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00929478A
Other languages
German (de)
English (en)
Other versions
EP1178832B1 (fr
Inventor
Michel Pairet
Richard Reichl
Alexander Walland
Karl-Heinz Bozung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP10183369A priority Critical patent/EP2269647A3/fr
Priority to EP10183392A priority patent/EP2266620A3/fr
Priority to EP03008310A priority patent/EP1327452A3/fr
Priority to EP10183425A priority patent/EP2269648A3/fr
Priority to EP10180233A priority patent/EP2266621A3/fr
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to SI200030181T priority patent/SI1178832T1/xx
Priority to EP05008960A priority patent/EP1570861A3/fr
Publication of EP1178832A1 publication Critical patent/EP1178832A1/fr
Application granted granted Critical
Publication of EP1178832B1 publication Critical patent/EP1178832B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Definitions

  • the present invention relates to new drug compositions based on long-acting anticholinergic compounds and long-acting ⁇ -mimetics, processes for their preparation and their use in the therapy of respiratory diseases.
  • the main effects may be general restlessness, agitation, insomnia, anxiety, tremors, sweating and headaches. Inhalation does not rule out these side effects, but they are generally somewhat less than after oral or parenteral use.
  • the side effects of the ß-sympathomimetics when used as an asthma agent are mainly due to the more or less pronounced ß1 -stimulating effects on the heart. They produce tachycardia, palpitations, angina-like complaints and arrhythmias [P.T. Ammon (ed.),
  • active ingredients can preferably be used as long-acting ⁇ -mimetics in the combination of active ingredients according to the invention: bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, pirbuterol, procaterol, reproterol, salmeterol, sulfonterol, terbutaline, tolubuterol, 4 7- [2 - ⁇ [2 - ⁇ [3- (2-phenylethoxy) propyl] sulfonyl ⁇ ethyl] - amino ⁇ ethyl] -2 (3H) -benzothiazolone,
  • Active ingredient combination used formoterol, salmeterol,
  • Formoterol or salmeterol particularly in the form of their racemates, their enantiomers, their diastereomers and their mixtures and, if appropriate, their pharmacologically acceptable acid addition salts, are particularly preferably used in the pharmaceutical compositions according to the invention as the ⁇ -mimetic.
  • the long-acting ⁇ -mimetics can be converted and used in the form of their physiologically and pharmacologically tolerable salts.
  • hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid can be used to prepare the acid addition salts.
  • Mixtures of the aforementioned acids can also be used.
  • the fumarate of formoterol (abbreviated to formoterol FU) is particularly preferred as a long-acting ⁇ -mimetic.
  • the active ingredient formoterol can be used as an enantiomer or diastereomer mixture or in the form of the individual enantiomers / diastereomers.
  • salmeterol can be used as the long-acting ⁇ -mimetic, optionally in the form of its racemates, enantiomers, of which the (R) -enantiomer is highly preferred, and optionally its pharmacologically acceptable acid addition salts.
  • Suitable long-acting anticholinergics are, in principle, compounds which are already known from the prior art, such as glycopyrronium bromide and esters of bi- and tricyclic amino alcohols, as are known from European laid-open specification 0 418 716 and international patent application WO 92/16528 and to which reference is hereby made in full is taken.
  • glycopyrronium bromide and esters of bi- and tricyclic amino alcohols as are known from European laid-open specification 0 418 716 and international patent application WO 92/16528 and to which reference is hereby made in full is taken.
  • R is an optionally halogen- or hydroxy-substituted C-
  • R 1 is hydrogen, OH, C 1 -C 4 -alkoxy or C 1 -C 4 -alkyl, which can optionally be substituted by hydroxy;
  • R 2 is a thienyl, phenyl, furyl, cyclopentyl or cyclohexyl radical, 5 these radicals also being methyl-substituted, thienyl and phenyl also being fluorine- or chlorine-substituted,
  • R 3 is hydrogen or a thienyl or phenyl radical which may optionally be substituted by halogen or CC 4 alkyl, w optionally in the form of their racemates, their enantiomers, their diastereomers and their mixtures.
  • the compounds of the formula (I) are particularly preferred as anti-cholinergic anti-cholinergics glycopyrronium bromide and as esters of bi- and tricyclic amino alcohols, in which
  • R is a methyl, ethyl or propyl group which is optionally substituted by fluorine or hydroxyl, 25 R 'is methyl, ethyl or propyl, preferably methyl, and the positive charge of the N atom is one equivalent of an anion X selected from the group consisting of chloride , Bromide and methanesulfonate, preferably bromide,
  • Y represents a single bond or an O atom
  • R 1 is hydrogen, OH, methoxy, ethoxy, propoxy, methyl, ethyl, propyl,
  • R 2 is a thienyl, phenyl or cyclohexyl radical, these radicals also being methyl-substituted, thienyl and phenyl also being fluorine or chlorine-substituted,
  • R 3 is hydrogen, or a thienyl or phenyl radical which may optionally be substituted by fluorine, chlorine or methyl, optionally in the form of their racemates, their enantiomers, their diastereomers and their mixtures.
  • compositions in which compounds of the formula (I) are used as anti-cholinergic agents, in which A is a radical of the general formula (II)
  • Y is an O atom
  • R 1 is hydrogen, OH or hydroxymethyl
  • R 2 is a thienyl, phenyl or cyclohexyl radical
  • R 3 is hydrogen, thienyl or phenyl, optionally in the form of their racemates, their enantiomers, their diastereomers and their mixtures.
  • Tiotropium salt is particularly preferred - in particular the tiotropium bromide [(1 ⁇ , 2ß, 4ß ) 5, 7ß) -7 - [(hydroxy-2-thienylacetyl) oxy] -9,9-dimethyl-3-oxa-9-azoniatricyclo [ 3.3.1.0 2,4 ] nonane bromide monohydrate - abbreviated Tiotropium BR] - used as an anticholinergic.
  • alkyl groups with 1 to 4 carbon atoms are considered as alkyl groups (also insofar as they are part of other radicals). Examples include: methyl, ethyl, propyl or butyl. Unless otherwise stated, the abovementioned names propyl and butyl encompass all of the possible isomeric forms.
  • propyl includes the two isomeric radicals n-propyl and iso-propyl, the term butyl n-butyl, iso-butyl, sec. Butyl and tert-butyl. If necessary, common abbreviations such as Me for methyl, Et for ethyl etc.
  • alkyl radicals mentioned above.
  • alkylene groups Branched and unbranched alkylene bridges with 4 to 6 carbon atoms are considered as alkylene groups. Examples include: butylene, pentylene, hexylene. Unless stated otherwise, all of the possible isomeric forms are included in the abovementioned designations butylene, pentylene and hexylene.
  • butylene includes the isomers n-butylene, 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene etc.
  • Halogen is generally referred to as fluorine, chlorine, bromine or iodine.
  • anion X is generally referred to as fluorine, chlorine, bromine, iodine, methanesulfonate, fumarate, citrate.
  • compositions according to the invention are preferably administered in the form of a dosage aerosol - but any other form of parenteral or oral administration is also possible.
  • metered dose inhalers embodies the preferred form of use, particularly in the treatment of obstructive pulmonary diseases or in the treatment of asthma.
  • the active substance combinations according to the invention can be applied by means of so-called nebulizers, with which solutions of pharmacologically active substances are sprayed under high pressure in such a way that mist of inhalable particles is formed.
  • nebulizers with which solutions of pharmacologically active substances are sprayed under high pressure in such a way that mist of inhalable particles is formed.
  • the medicinal products intended for inhalation are usually dissolved in an aqueous or ethanolic solution, solvent mixtures of water and ethanol also being suitable, depending on the solution properties of the active compounds.
  • nebulizers are described, for example, in PCT patent application WO91 / 14468 and in the international patent application with the file number PCT / EP96 / 04351, to which reference is hereby made.
  • active substance-containing solutions of defined volumes are sprayed through small nozzles using high pressures, so that inhalable aerosols with a preferred particle size of between 1 and 10, preferably between 2 and 5, micrometers are formed .
  • the solvents for drug preparation include Mixtures suitable, for example containing ethanol as a solvent.
  • cosolvents are those which contain hydroxyl groups or other polar groups, for example alcohols - in particular isopropyl alcohol, glycols - in particular propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • Cosolvents are suitable for increasing the solubility of auxiliary substances and, where appropriate, of the active substances.
  • preservatives in particular benzalkonium chloride
  • benzalkonium chloride can be added.
  • the preferred amount of preservative, especially benzalkonium chloride is between 8 and 12 mg / 100 ml of solution.
  • complexing agents can be added to the active ingredient combination.
  • Suitable complexing agents are those that are pharmacologically acceptable, especially those that have already been approved under pharmaceutical law. EDTA,
  • Nitrilotriacetic acid citric acid and ascorbic acid as well as their salts.
  • the disodium salt of ethylenediamtetraacetic acid is particularly preferred.
  • the proportion of the dissolved active ingredient combination in the finished pharmaceutical preparation is between 0.001 and 5% - preferably between 0.005 and 3%, in particular 0.01 to 2%.
  • the maximum concentration of the drug depends on the solubility in the solvent and on the dosage required to achieve the desired therapeutic effect.
  • the following preparation forms are given as examples:
  • the active ingredient combinations according to the invention can also be inhaled in the form of a powder.
  • the production of such dosage forms is known from the prior art.
  • they contain pharmacologically acceptable carriers or auxiliaries - such as microcrystalline lactose.
  • the dose intended for inhalation can, for example, be filled into capsules and has e.g. following composition:
  • Pentobarbital sodium (Nembutal®) slowly injected intravenously. The animals are at 1.0 mg / kg IV. Suxamethonium relaxes.
  • the animals are ventilated with room air and oxygen (4: 1) using a 900 C servo fan (Siemens), frequency 15 / min.,
  • a pressure tube (meat No. 1), which is installed immediately in front of the orotracheal tube, a differential pressure transducer and amplifier DCB-4C.
  • a differential pressure transducer and amplifier DCB-4C.
  • One catheter is placed in the trachea and a second (balloon) catheter in the lung section of the esophagus. Both are connected to a differential pressure transducer and amplifier to determine the transpulmonary pressure.
  • a respiratory mechanics calculator (IFD-Mühlheim) determines the pulmonary resistance (R) from the registered pressure values.
  • a computer program VAS-1 LA (IFD-Mühlheim) determines:
  • Heart rate is recorded using an EKG (limb lead II) and cardiotachometer.
  • bronchospasms are generated by iv injection of 10 ⁇ g / kg acetylcholine chloride, which are 2-3 times within approx. 10 min. Distance to be repeated.
  • the test substances tiotropium bromide, formoterol fumarate and the combination of both substances are administered as aqueous solutions with the BINEB atomizer (Respimat®).
  • the combination is applied with the individual components at intervals of approx. 1 min.
  • the trigger mechanism is at the end of the The expiration phase and the atomized solution are pressed into the tracheobronchial tree by a respiratory pump in the following inspiration phase.
  • Formoterol fumarate 3 and 10 ⁇ g / 15 ⁇ l
  • Tiotropium bromide + formoterol fumarate 3 + 3 ⁇ g or 10 + 10 ⁇ g / 15 ⁇ l
  • Tables 1-6 show the initial values and the values after substance treatment over the time of 180 min.
  • Figures 1-2 show the percentage inhibitions of pulmonary resistance increases induced by ACh over a period of 180 min. shown.
  • results The results are shown in the tables and in the figures. 3 and 10 ⁇ g tiotropium bromide or formoterol fumarate inhibit the bronchial resistance increased by intravenous injection of ACh in a dose-graded manner and clearly.
  • the maximum bronchospasmolytic effect of Formoterol FU occurs rapidly with both doses, that of Tiotropium BR delays after about 60 min.
  • the duration of action of Formoterol FU is relatively short, especially with the low doses, and that of the Tiotropium BR as expected until the end of the test (180 min.).
  • Tiotropium bromide alone has no effect on the heart rate with either 3 ⁇ g or 10 ⁇ g.
  • Formoterol FU increases it in a dose-graded manner and above all with the high dosage by a maximum of over 90%. At the end of the test, values of over 80% are still measured. With the combinations 3 + 3 ⁇ g, however Even 10 + 10 ⁇ g tiotropium bromide and formoterol fumarate have significantly weakened the frequency effects and are below 30%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention concerne de nouvelles compositions médicamenteuses à base de composés à action anticholinergique prolongée et de bêtamimétiques à effet prolongé, leur procédé de production et leur utilisation dans le traitement d'affections des voies respiratoires.
EP00929478A 1999-05-12 2000-05-03 Nouvelles compositions medicamenteuses a base de bromide de tiotropium et de salmeterol Expired - Lifetime EP1178832B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP10183392A EP2266620A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP03008310A EP1327452A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183425A EP2269648A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10180233A EP2266621A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183369A EP2269647A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
SI200030181T SI1178832T1 (en) 1999-05-12 2000-05-03 Novel medicament compositions, based on tiotropium bromide and salmeterol
EP05008960A EP1570861A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19921693 1999-05-12
DE19921693A DE19921693A1 (de) 1999-05-12 1999-05-12 Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PCT/EP2000/003943 WO2000069468A1 (fr) 1999-05-12 2000-05-03 Nouvelles compositions medicamenteuses a base de composes a action anticholinergique et de betamimetiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP03008310A Division EP1327452A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques

Publications (2)

Publication Number Publication Date
EP1178832A1 true EP1178832A1 (fr) 2002-02-13
EP1178832B1 EP1178832B1 (fr) 2003-07-30

Family

ID=7907709

Family Applications (7)

Application Number Title Priority Date Filing Date
EP03008310A Ceased EP1327452A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP05008960A Withdrawn EP1570861A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183425A Withdrawn EP2269648A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183392A Withdrawn EP2266620A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP00929478A Expired - Lifetime EP1178832B1 (fr) 1999-05-12 2000-05-03 Nouvelles compositions medicamenteuses a base de bromide de tiotropium et de salmeterol
EP10180233A Withdrawn EP2266621A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183369A Withdrawn EP2269647A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques

Family Applications Before (4)

Application Number Title Priority Date Filing Date
EP03008310A Ceased EP1327452A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP05008960A Withdrawn EP1570861A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183425A Withdrawn EP2269648A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183392A Withdrawn EP2266620A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP10180233A Withdrawn EP2266621A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques
EP10183369A Withdrawn EP2269647A3 (fr) 1999-05-12 2000-05-03 Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques

Country Status (41)

Country Link
US (3) US6455524B1 (fr)
EP (7) EP1327452A3 (fr)
JP (5) JP4612956B2 (fr)
KR (2) KR100841909B1 (fr)
CN (2) CN1250290C (fr)
AR (1) AR023972A1 (fr)
AT (1) ATE245976T1 (fr)
AU (1) AU775588B2 (fr)
BG (1) BG65189B1 (fr)
BR (1) BR0010498A (fr)
CA (1) CA2368583C (fr)
CO (1) CO5140068A1 (fr)
CZ (1) CZ302328B6 (fr)
DE (2) DE19921693A1 (fr)
DK (1) DK1178832T3 (fr)
EA (1) EA004657B1 (fr)
EE (4) EE201000018A (fr)
ES (1) ES2203470T3 (fr)
HK (1) HK1043064B (fr)
HR (1) HRP20010828A2 (fr)
HU (1) HUP0201103A3 (fr)
IL (3) IL146119A0 (fr)
ME (1) MEP36608A (fr)
MX (1) MXPA01011400A (fr)
MY (2) MY134222A (fr)
NO (2) NO328423B1 (fr)
NZ (1) NZ515596A (fr)
PE (1) PE20010133A1 (fr)
PL (2) PL206146B1 (fr)
PT (1) PT1178832E (fr)
RS (2) RS50269B (fr)
SA (1) SA00210064B1 (fr)
SG (4) SG175465A1 (fr)
SI (1) SI1178832T1 (fr)
SK (1) SK287072B6 (fr)
TR (2) TR200901979T2 (fr)
TW (2) TWI272106B (fr)
UA (1) UA74547C2 (fr)
UY (1) UY26139A1 (fr)
WO (1) WO2000069468A1 (fr)
ZA (1) ZA200108942B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1326642A2 (fr) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Preparations pharmaceutiques de catecholamine et procedes
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
DE10206505A1 (de) * 2002-02-16 2003-08-28 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
US20020111363A1 (en) * 2000-10-31 2002-08-15 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002085296A2 (fr) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, et formulations de traitement de maladies respiratoires et pulmonaires a l'aide de steroides non-glucocorticoides et/ou d'ubiquinone et d'un agent broncho-dilatateur
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003013633A1 (fr) * 2001-08-09 2003-02-20 Glaxo Group Limited Dispositif d'inhalation a composition pharmaceutique
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
JP2005504076A (ja) * 2001-09-14 2005-02-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な吸入用医薬組成物
US7309707B2 (en) * 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) † 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
MXPA04009583A (es) * 2002-04-04 2005-01-11 Boehringer Ingelheim Pharma Nuevas formulaciones en polvo adecuadas para inhalacion.
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE10216427A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittelkompositionen enthaltend heterocyclische Verbindungen und ein neues Anticholinergikum
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
US20040048887A1 (en) * 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
DE10351663A1 (de) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (fr) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyle et composes apparentes ayant les activites agoniste du recepteur beta2 adrenergique et antagoniste de recepteur de muscarinic
DE602004021921D1 (de) * 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
BRPI0413129A (pt) * 2003-07-29 2006-10-03 Boehringer Ingelheim Int medicamentos para inalação compreendendo betamiméticos e anticolinérgico
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
DE10345065A1 (de) 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
CA2543858C (fr) 2003-11-21 2014-04-15 Theravance, Inc. Composes ayant une activite agoniste de recepteur adrenergique beta 2 et antagoniste de recepteur muscarinique
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
PL1718336T3 (pl) * 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego
SI1713471T1 (sl) * 2004-02-06 2012-07-31 Meda Pharma Gmbh & Co Kg Kombinacija antiholinergikov in inhibitorjev fosfodiesteraze tipa za zdravljenje respiratornih bolezni
EP1718304A1 (fr) * 2004-02-20 2006-11-08 Boehringer Ingelheim International GmbH Compositions pharmaceutiques a base d'anticholinergiques et de pegsunercept
US20060189524A1 (en) * 2004-02-20 2006-08-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and pegsunercept
US20050186175A1 (en) * 2004-02-20 2005-08-25 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on benzilic acid esters and soluble TNF receptor fusion proteins
US7507745B2 (en) 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
WO2005087722A1 (fr) * 2004-03-11 2005-09-22 Theravance, Inc. Composes biphenyle convenant en tant qu'antagonistes du recepteur muscarinique
WO2005087763A1 (fr) * 2004-03-11 2005-09-22 Theravance, Inc. Composes de diphenylmethyle, antagonistes du recepteur muscarinique
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
AU2006224842B2 (en) * 2005-03-16 2011-09-29 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EP1879571A1 (fr) * 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Combinaison de medicaments a inhaler contenant un betamimetique et un steroide en plus d'un anticholinergique
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
EP2085396A3 (fr) * 2005-05-02 2009-11-25 Boehringer Ingelheim International Gmbh Nouvelles formules cristallines de bromure de tiotropium
MX2007015997A (es) * 2005-06-15 2008-03-07 Boehringer Ingelheim Int Procedimiento para preparar nuevas sales de tiotropio, nuevas sales de tiotropio como tales y composiciones farmaceuticas de las mismas.
EP1959942A1 (fr) * 2005-08-06 2008-08-27 Boehringer Ingelheim International GmbH Procédé pour le traitement de la dyspnée comprenant l' administration combinée de sels de tiotropium et de sels de salmétérol
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
RU2465915C2 (ru) 2005-12-21 2012-11-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных заболеваний
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2009538361A (ja) * 2006-05-26 2009-11-05 デイ・リミテッド・パートナーシップ ４級アンモニウムムスカリン受容体アンタゴニストの噴霧可能組成物
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CA2608561A1 (fr) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Support d'accessoires de deflecteur pour motocyclette
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN107412212B (zh) 2009-05-29 2021-01-22 珍珠治疗公司 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
ES2552538T3 (es) 2011-06-10 2015-11-30 Chiesi Farmaceutici S.P.A. Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
WO2012168349A1 (fr) 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Composés ayant une activité antagoniste des récepteurs muscariniques et une activité agoniste des récepteurs adrénergique bêta-2
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
TW201311649A (zh) * 2011-09-05 2013-03-16 Everlight Chem Ind Corp 用於太陽能電池電解液之化合物及其製法、含有該化合物之電解液及太陽能電池
HUE037944T2 (hu) 2012-12-06 2018-09-28 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek
CA2893627C (fr) 2012-12-06 2021-09-14 Chiesi Farmaceutici S.P.A. Composes ayant une activite antagoniste du recepteur muscarinique et agoniste du recepteur beta2 adrenergique
CA2905542C (fr) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Procedes et systemes de conditionnement de matieres cristallines particulaires
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (fr) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Composés ayant une activité d'antagoniste des récepteurs muscariniques et d'agoniste des récepteurs adrénergiques bêta2
WO2018011090A1 (fr) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Composés d'hydroxyquinolinone ayant une activité d'antagoniste des récepteurs muscariniques et d'agoniste des récepteurs adrénergiques bêta2
WO2018069887A1 (fr) * 2016-10-14 2018-04-19 Glenmark Specialty S.A. Compositions nébulisables de tiotropium et de formotérol
MY196804A (en) 2016-12-14 2023-05-03 Beijing Showby Pharmaceutical Co Ltd Class of bifunctional compounds with quaternary ammonium salt structure
US11331248B2 (en) 2017-01-31 2022-05-17 Alphinity Usa, Inc. Bioprocess vessels with integrated pump

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FR2651678B1 (fr) * 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
DK1086688T3 (da) * 1991-12-18 2004-08-16 Minnesota Mining & Mfg Aerosolformuleringer til suspensioner
RU2126248C1 (ru) * 1992-12-09 1999-02-20 Берингер Ингельхейм Фармасьютикалз, Инк. Жидкая фармацевтическая композиция в форме аэрозоля
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000006121A1 (fr) * 1998-07-24 2000-02-10 Jago Research Ag Formulations pour aerosols a usage medical
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
DE19847970A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähige Wirkstoff-Formulierung
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0069468A1 *

Also Published As

Publication number Publication date
EE201000018A (et) 2010-04-15
EP1327452A2 (fr) 2003-07-16
CA2368583C (fr) 2010-01-05
RS50269B (sr) 2009-07-15
SG179293A1 (en) 2012-04-27
SK287072B6 (sk) 2009-11-05
SG175465A1 (en) 2011-11-28
US20020115681A1 (en) 2002-08-22
KR100841909B1 (ko) 2008-06-30
JP2006188534A (ja) 2006-07-20
UY26139A1 (es) 2000-12-29
SG158731A1 (en) 2010-02-26
AU4754500A (en) 2000-12-05
CN1839833A (zh) 2006-10-04
ES2203470T3 (es) 2004-04-16
TW200505483A (en) 2005-02-16
NO20093464L (no) 2001-11-02
PL199442B1 (pl) 2008-09-30
PT1178832E (pt) 2003-12-31
ATE245976T1 (de) 2003-08-15
UA74547C2 (en) 2006-01-16
NO328423B1 (no) 2010-02-15
JP2011021038A (ja) 2011-02-03
HK1043064A1 (en) 2002-09-06
NO20015359L (no) 2001-11-02
JP4612956B2 (ja) 2011-01-12
EP2266621A3 (fr) 2013-01-23
IL172695A (en) 2011-07-31
NO20015359D0 (no) 2001-11-02
SG178626A1 (en) 2012-03-29
EE05193B1 (et) 2009-08-17
US6455524B1 (en) 2002-09-24
AR023972A1 (es) 2002-09-04
KR20020001876A (ko) 2002-01-09
HK1043064B (zh) 2006-08-18
SI1178832T1 (en) 2003-12-31
JP2011021037A (ja) 2011-02-03
RS20090083A (en) 2009-07-15
EP2266620A2 (fr) 2010-12-29
PE20010133A1 (es) 2001-03-02
DK1178832T3 (da) 2003-11-03
DE19921693A1 (de) 2000-11-16
IL146119A (en) 2006-08-01
ZA200108942B (en) 2002-08-26
US6630466B2 (en) 2003-10-07
PL206146B1 (pl) 2010-07-30
EE05677B1 (et) 2013-10-15
EP2269648A3 (fr) 2012-04-18
EP1178832B1 (fr) 2003-07-30
WO2000069468A1 (fr) 2000-11-23
CO5140068A1 (es) 2002-03-22
EA200101156A1 (ru) 2002-06-27
JP2002544239A (ja) 2002-12-24
KR100962059B1 (ko) 2010-06-10
HRP20010828A2 (en) 2003-02-28
MY134222A (en) 2007-11-30
HRP20010828B1 (fr) 2013-01-31
SK16372001A3 (sk) 2002-03-05
EP2269648A2 (fr) 2011-01-05
DE50003116D1 (de) 2003-09-04
EE201000020A (et) 2010-04-15
EP2266621A2 (fr) 2010-12-29
PL352131A1 (en) 2003-07-28
TWI272106B (en) 2007-02-01
IL146119A0 (en) 2002-07-25
SA00210064B1 (ar) 2006-08-12
EP1327452A3 (fr) 2004-01-21
MEP36608A (en) 2011-02-10
NZ515596A (en) 2003-10-31
AU775588B2 (en) 2004-08-05
MY129512A (en) 2007-04-30
TR200901979T2 (tr) 2009-05-21
MXPA01011400A (es) 2002-06-04
CA2368583A1 (fr) 2000-11-23
EA004657B1 (ru) 2004-06-24
BG106095A (en) 2002-06-28
CZ302328B6 (cs) 2011-03-16
BG65189B1 (bg) 2007-06-29
CN1350465A (zh) 2002-05-22
EE200100594A (et) 2003-02-17
KR20070050507A (ko) 2007-05-15
HUP0201103A2 (hu) 2002-09-28
EP2269647A3 (fr) 2012-04-18
EP2269647A2 (fr) 2011-01-05
EP2266620A3 (fr) 2012-04-18
TR200103233T2 (tr) 2002-04-22
YU71901A (sh) 2005-07-19
CZ20014055A3 (cs) 2002-02-13
IL172695A0 (en) 2006-04-10
BR0010498A (pt) 2002-02-26
CN1250290C (zh) 2006-04-12
EP1570861A3 (fr) 2010-12-29
JP2011021036A (ja) 2011-02-03
EE201000019A (et) 2010-04-15
HUP0201103A3 (en) 2008-10-28
EP1570861A2 (fr) 2005-09-07
US6433027B1 (en) 2002-08-13

Similar Documents

Publication Publication Date Title
EP1178832A1 (fr) Nouvelles compositions medicamenteuses a base de composes a action anticholinergique et de betamimetiques
EP1335728B1 (fr) Compositions de medicaments a base de sels de tiotropium et de sels de salmeterol
US20040002548A1 (en) Medicament compositions containing anticholinergically-effective compounds and betamimetics
KR102618119B1 (ko) 말의 기도 질환의 치료를 위한 무스카린 길항제 및 이의 병용물
US20100197719A1 (en) Medicament compositions containing anticholinergically-effective compounds and betamimetics
EP1879571A1 (fr) Combinaison de medicaments a inhaler contenant un betamimetique et un steroide en plus d'un anticholinergique
EP1429768B1 (fr) Agents pharmaceutiques d'inhalation
EP1631287A2 (fr) Nouvelles combinaisons medicamenteuses a action prolongee utilisees pour traiter des maladies des voies respiratoires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20011212;LV PAYMENT 20011212;RO PAYMENT 20011212;SI PAYMENT 20011212

17Q First examination report despatched

Effective date: 20030122

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/46 B

Ipc: 7A 61K 31/535 B

Ipc: 7A 61P 11/00 B

Ipc: 7A 61K 31/137 A

Ipc: 7A 61K 31/4741 B

RTI1 Title (correction)

Free format text: NOVEL MEDICAMENT COMPOSITIONS, BASED ON TIOTROPIUM BROMIDE AND SALMETEROL

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/4741 B

Ipc: 7A 61K 31/46 B

Ipc: 7A 61K 31/137 A

Ipc: 7A 61K 31/535 B

Ipc: 7A 61P 11/00 B

RTI1 Title (correction)

Free format text: NOVEL MEDICAMENT COMPOSITIONS, BASED ON TIOTROPIUM BROMIDE AND SALMETEROL

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOZUNG, KARL-HEINZ

Inventor name: REICHL, RICHARD

Inventor name: PAIRET, MICHEL

Inventor name: WALLAND, ALEXANDER

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20030730

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: GERMAN

REF Corresponds to:

Ref document number: 50003116

Country of ref document: DE

Date of ref document: 20030904

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030403940

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2203470

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040504

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: FR

Ref legal event code: RN

REG Reference to a national code

Ref country code: FR

Ref legal event code: FC

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: FR

Effective date: 20100331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20140527

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20140514

Year of fee payment: 15

Ref country code: IE

Payment date: 20140526

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20140521

Year of fee payment: 15

Ref country code: AT

Payment date: 20140513

Year of fee payment: 15

Ref country code: SE

Payment date: 20140520

Year of fee payment: 15

Ref country code: FI

Payment date: 20140513

Year of fee payment: 15

Ref country code: PT

Payment date: 20140502

Year of fee payment: 15

Ref country code: CH

Payment date: 20140521

Year of fee payment: 15

Ref country code: GR

Payment date: 20140519

Year of fee payment: 15

Ref country code: IT

Payment date: 20140528

Year of fee payment: 15

Ref country code: ES

Payment date: 20140528

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20140523

Year of fee payment: 15

Ref country code: DK

Payment date: 20140521

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20140429

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20151103

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20150531

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM9D

Effective date: 20150503

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 245976

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150503

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150531

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150503

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150503

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150531

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150601

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151208

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20151215

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20150601

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151103

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150503

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150504

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150503

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20030403940

Country of ref document: GR

Effective date: 20151208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150531

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150601

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150503

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150504

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150531

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190521

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190522

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190521

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 50003116

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20200502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20200502